Avacta Group Equity 2024

Avacta Group Aktienanalyse

What does Avacta Group do?

Avacta Group PLC is a British company specializing in the development of innovative solutions for biotechnology and diagnostics. It was founded in 2004 by Eliot Forster and is headquartered in Wetherby, West Yorkshire. Avacta's history began with the development of Affimer technology, which offers an alternative to conventional antibodies. Affimers are synthetic peptides with high binding affinity to biological molecules, making them important tools for biomedical research and diagnostic applications. The company had limited resources in its early years, and it took several years to complete the development of Affimer technology. In recent years, Avacta has expanded its business model by offering licensed services to pharmaceutical companies. The company provides innovative screening methods and drug discovery tools based on Affimer technology. Avacta has partnerships with major companies such as LG Chem, Moderna, and Wockhardt. The partnership with LG Chem aims to use the platform technology for the development of Covid-19 therapeutics, while the collaboration with Wockhardt focuses on the creation of diagnostic kits and test systems. Avacta's main business areas are biotechnology and diagnostics. The biotechnology division offers screening services for pharmaceutical companies, with a focus on developing higher quality and more efficient antibodies using Affimers, which potentially provide better screening results than traditional antibodies. In the field of diagnostics, the company is working on the development of diagnostic test systems for disease diagnosis. Avacta has started developing diagnostic test kits for Covid-19 that can be used in a laboratory or at home. The company also has a partnership with Adeptrix, a diagnostic tool manufacturing company. Another important area of Avacta is therapeutic applications. Avacta's Affimer technology has already led to new clinical approaches in the development of cancer therapies. Avacta also has a pipeline program of Affimer therapeutics targeting various diseases, from cancer to inflammatory and neurodegenerative diseases. Avacta's products include licensed services for pharmaceutical companies, research kits for Affimer technology, and its own portfolio of Affimer products for various applications in research and diagnostics. The products are exported worldwide, and the company has offices in the United States and South Korea. Overall, Avacta Group PLC has become a major player in the biotechnology and diagnostics industry by expanding its Affimer technology to various applications. Partnerships with major pharmaceutical companies and the development of diagnostic test systems for Covid-19 have brought the company into the public eye and contribute to strengthening its position as a leading provider of Affimer technology in the industry. Avacta Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Avacta Group's Equity

Avacta Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Avacta Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Avacta Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Avacta Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Avacta Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Avacta Group stock

What is the equity of Avacta Group this year?

Avacta Group has equity of 0 GBP this year.

What was the equity of Avacta Group compared to the previous year?

The equity of Avacta Group has increased/decreased by -100% decreased compared to the previous year.

What impact does a high equity have on investors of Avacta Group?

A high equity is advantageous for investors of Avacta Group as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Avacta Group?

A low equity can be a risk for investors of Avacta Group, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Avacta Group affect the company?

An increase in equity of Avacta Group can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Avacta Group affect the company?

A reduction in equity of Avacta Group can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Avacta Group?

Some factors that can affect the equity of Avacta Group include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Avacta Group so important for investors?

The equity of Avacta Group is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Avacta Group take to change the equity?

To change equity, Avacta Group can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Avacta Group pay?

Over the past 12 months, Avacta Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avacta Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of Avacta Group?

The current dividend yield of Avacta Group is .

When does Avacta Group pay dividends?

Avacta Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avacta Group?

Avacta Group paid dividends every year for the past 0 years.

What is the dividend of Avacta Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avacta Group located?

Avacta Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avacta Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avacta Group from 12/4/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did Avacta Group pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of Avacta Group in the year 2023?

In the year 2023, Avacta Group distributed 0 GBP as dividends.

In which currency does Avacta Group pay out the dividend?

The dividends of Avacta Group are distributed in GBP.